Yanuki
Pharmaceuticals / Sleep Disorders
Eli Lilly and Company is set to acquire Centessa Pharmaceuticals for a potential total of $7.8 billion. This acquisition aims to advance treatments for sleep-wake disorders by leveraging Centessa's orexin receptor 2 (OX2R) agonists, which h...
Finance / Stocks
Eli Lilly (LLY) has become a dominant player in the obesity market, largely driven by its GLP-1 injections Mounjaro and Zepbound. However, despite strong sales growth, Lilly's shares fell after an HSBC downgrade citing pricing pressures and...
Finance / Stocks
Eli Lilly (LLY) faces a setback in the weight loss drug market as its oral GLP-1 candidate, orforglipron, experiences FDA review delays. This article examines the implications and explores alternative investment opportunities in the pharmac...
Finance / Stocks
Alphabet (GOOGL, GOOG) is demonstrating significant growth and potential in the artificial intelligence (AI) sector, making it a compelling investment for 2026 and beyond. With strong financial results and strategic AI investments, Alphabet...
Business / Health Science
Eli Lilly has achieved a $1 trillion market capitalization, marking the first time a healthcare company has reached this valuation, previously dominated by tech firms. This milestone is driven by the surging demand for its weight loss injec...
Finance / Stocks
Eli Lilly's tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, has become the world's top-selling drug, surpassing Merck's Keytruda. This reflects the increasing demand for GLP-1 drugs and Eli Lilly's strong market pos...
Finance / Stock News
Apple (AAPL) and Eli Lilly (LLY) have experienced volatility but are now rebounding, presenting potential opportunities for growth and income investors. This article examines the factors driving their resurgence.
Health / Weight Loss
The once-promising obesity drug market faces a turning point as investor enthusiasm cools amidst concerns over lackluster results, potential copycat drugs, and pricing pressures. Pharmaceutical giants Novo Nordisk and Eli Lilly are now unde...
Finance / Stocks
Eli Lilly and Company (NYSE:LLY) has garnered attention in the stock market, with Wall Street analysts offering varied perspectives on its potential. Recent reports highlight both optimistic upgrades and cautionary downgrades, reflecting th...
Business / Pharmaceuticals
Eli Lilly (LLY) is witnessing robust demand for its diabetes and weight-loss drug, Mounjaro, in India, driven by increasing rates of obesity and diabetes. The company is focused on meeting this rising demand, positioning Mounjaro as a key p...
Finance / Healthcare
The healthcare sector is facing a confluence of challenges, including potential tariffs on pharmaceuticals, increasing regulatory scrutiny, and evolving financial strategies. These factors are creating uncertainty and volatility in the mark...
Finance / Pharmaceuticals
Eli Lilly (LLY) reported first-quarter 2025 earnings that exceeded expectations, driven by strong sales of its weight loss drug Zepbound and diabetes treatment Mounjaro. However, the pharmaceutical giant lowered its full-year profit outlook...
